Surgery Today

, Volume 27, Issue 8, pp 719–725 | Cite as

Technique and results of regional hyperthermic cytostatic arm perfusion for malignant melanoma

  • Peter Würl
  • Uwe Eichfeld
  • Hans-Dieter Pauer
  • Albrecht Gläser
  • Uwe Rose
  • Henning Dralle
Original Articles

Abstract

Isolated hyperthermic cytostatic limb perfusion has been established as an efficient procedure for the treatment of malignant melanoma of the limbs. However, perfusions of the upper extremities are generally carried out much less frequently than would be expected given the distribution pattern of malignant melanoma and sarcoma. Thus, isolated descriptions of treatment results for perfusion of the upper extremities are not available. Between 1991 and 1994, arm perfusions using melphalan 1.0mg/kg body weight were given to 14 patients with malignant melanoma, using the standardized method of perfusion described herein. Within an average observation period of 34.9 months (range, 12–65 months), 11 (78.7%) of the 14 patients who had M.D. Anderson stage II–IV melanoma remained free of local recurrence. In fact, 10 (71.6%) of the patients were still alive at the end of the observation period. None of the 14 patients showed any systemic adverse effects, although 1 patient developed a lymphedema 32 months after perfusion and 2 patients showed a postoperative temporary neurologic deficit. These results demonstrate that isolated perfusion of the upper limb with heat and melphalan under standardized conditions remains the treatment of choice for melanoma of the arm, as for melanoma of the leg, without a higher rate of complications.

Key Words

arm perfusion melphalan melanoma recurrence survival 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Eichfeld U, Gläser A, Schneider G, Kraus J, Pauer HJ, Schwarz I (1993) Die regionale zytostatische Extremitätenperfusion bei Patienten mit malignem Melanom und Weichteilsarkom —therapeutische Anwen-dungen und Ergebnisse. Zentralbl Chir 118:63–68PubMedGoogle Scholar
  2. 2.
    Hohenberger W, Meyer T, Göhl J (1994) Extremitätenperfusion beim malignen Melanom. Chirurg 65:175–185PubMedGoogle Scholar
  3. 3.
    Kettelhach C, Kraus T, Hupp T, Manner M, Schlag P (1990) Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Eur J Surg Oncol 16:370–375Google Scholar
  4. 4.
    Hafstrom L, Rudenstam CM, Blomquist E, Ingvar C, Jonsson PE, Lagerlof B, Lindholm C, Ringborg U, Westman G, Ostrup L (1991) Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 9:2091–2094PubMedGoogle Scholar
  5. 5.
    Ghussen F, Krüger I, Groth W, Stützer H (1988) The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 61:654–659PubMedGoogle Scholar
  6. 6.
    Krementz ET, Carter RD, Sutherland CM, Campbell M (1979) The use of regional chemotherapy in the management of malignant melanoma. World J Surg 3:289–294PubMedCrossRefGoogle Scholar
  7. 7.
    Krementz ET, Ryan RF, Muchmore JH, Carter RD (1992) Hyperthermic regional perfusion for melanoma of the limbs. In: Balch CM, Houghton AN, Milton GW, Soober AJ, Soong SJ (eds) Cutaneous melanoma. Lippincott, Philadelphia, pp 403–421Google Scholar
  8. 8.
    Creech O Jr, Kremenz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporal circuit. Ann Surg 148:616–632PubMedGoogle Scholar
  9. 9.
    Cavalière R, Ciogatto EC, Giovanella BC, Heidelberger C, Johnson RO, Margottini M, Mondovi B, Moricca G, Rossi-Fanelli A (1967) Selective heat sensitivity of cancer cells: Biochemical and clinical studies. Cancer 20:1351–1381PubMedGoogle Scholar
  10. 10.
    Oleson JR, Calderwood SK, Couglin CT, Dewhirst MW, Gerweck LE, Gibbs FA, Kapp DS (1988) Biological and clinical aspects of hyperthermia in cancer therapy. Am J Clin Oncol 11:368–380PubMedGoogle Scholar
  11. 11.
    Pace M, Filomena A, Galli A (1991) Thermal induction and temperature control in the hyperthermic antiblastic regional perfusion with extracorporeal circulation. Adv Exp Med Biol 267:399–406Google Scholar
  12. 12.
    Strom R, Crifo C, Rossi-Fanelli A (1977) Biochemical aspects of heat sensivity of tumour cells. In: Selective heat sensitivity of cancer cells. Recent Results Cancer Res 59:229–241Google Scholar
  13. 13.
    Stehlin JS, Giovanella BC, de Ipolyi PD, Muenz LR, Anderson RF (1975) Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 140:339–348PubMedGoogle Scholar
  14. 14.
    Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52–58PubMedGoogle Scholar
  15. 15.
    Sigurdsson GH, Nachbur B, Lejeune FJ (1993) Anesthesiologist's management of isolated limb perfusion with “high-dose” tumor necrosis factor alpha. Anesthesiology 79:1433–1437PubMedGoogle Scholar
  16. 16.
    Lienard D, Lejeune FJ, Ewalenko P (1992) In transit metastases of malignant melanoma treated by high dosr rTNF alpha in combination with interferon gamma and melphalan in isolation perfusion. World J Surg 16:234–240PubMedGoogle Scholar
  17. 17.
    Vaglini M, Belli F, Ammatuna M, Inglese MG, Manzi R, Prada A, Persiani L, Santinami M, Santoro N, Cascinelli N (1994) Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma interferon, and melphalan. Cancer 73:483–492PubMedGoogle Scholar
  18. 18.
    Kroon BBR (1988) Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol 14:101–106PubMedGoogle Scholar
  19. 19.
    Rauschecker HF, Foth H, Michaelis HC, Horst F, Gatzemeier W, Willenbrock D, Voth E, Kahl GF (1991) Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb. Cancer Chemother Pharmacol 27:379–384PubMedCrossRefGoogle Scholar
  20. 20.
    Thompson JF, Gianoutsos MP (1992) Isolated limbs perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 16:227–233PubMedGoogle Scholar
  21. 21.
    Hoeckstra HJ, Schraffordt Koops H, de Vries LGE, van Weerden TW, Oldhoff J (1993) Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer 72:1224–1229Google Scholar
  22. 22.
    Lejeune FJ, Lienard D, El Douahy M, Seyedi JV, Ewalenko P (1989) Results of 206 isolated limb perfusions for malignant melanoma. Eur J Surg Oncol 15:510–519PubMedGoogle Scholar
  23. 23.
    Hohenberger W (1990) Isolation perfusion for malignant melanomas: established facts and parameters to be clarrified. In: Jakesz R, Rainer H (eds) Progress in regional cancer therapy. Springer, Berlin Heidelberg New York, pp 182–197Google Scholar
  24. 24.
    Krementz ET (1987) Regional perfusion for melanoma of the limbs: prospects for cooperative studies in North America. In: Veronesi U, Cascinelli N, Santinami M (eds) Cutaneous melanoma. Status of knowledge and future perspetive. Academic, London, pp 589–611Google Scholar
  25. 25.
    Schraffordt Koops H, Kroon BB, Oldhoff J, Hoekstra HJ (1992) Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of extremities. World J Surg; 16:241–245PubMedGoogle Scholar
  26. 26.
    Mastrangelo MJ, Baker AR, Katz HR (1985) Cutaneous melanoma. In: De Vita VT, Hellmann S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Philadelphia, pp 1124–1170Google Scholar
  27. 27.
    Chang AE, Rees RS (1993) Cutaneous neoplasms. In: Greenfield LJ, Mulholland MW, Oldham KT, Zelenock GB (eds) Surgery: scientific principles and practice. Lippincott, Philadelphia, pp 2019–2035Google Scholar
  28. 28.
    Hölzle E, Kind P, Plewig G (1991) Pigmentierte Hautverän derungen: Klinik — Histopathologie — Differentialdiagnosen. Schattauer, Stuttgart, pp 1–128Google Scholar
  29. 29.
    Cumberlin R, de Moss E, Lassus M, Friedman M (1985) Isolation perfusion for malignant melanoma of the extremity: a review. J Clin Oncol 3:1022–1032PubMedGoogle Scholar
  30. 30.
    Ghussen F, Krüger I, Groth W, Stützer H (1986) Randomisierte Melanomstudie zur Extremitätenperfusion. Behandlungsergebnisse 2 1/2 Jahre nach vorzeitigem Abbruch. Chirurg 57:619–624PubMedGoogle Scholar
  31. 31.
    Janoff KA, Moseson D, Nohlgren J, Davenport C, Richards C, Fletcher WS (1982) The treatment of stage I melanoma of the extremities with regional hyperthermic isolation perfusion. Ann Surg 196:316–323PubMedGoogle Scholar
  32. 32.
    Krementz ET (1986) Regional perfusion. Current sophistication, what next? Cancer 57:416–419PubMedGoogle Scholar
  33. 33.
    Martijn H, Oldhoff J, Schraffordt Koops H (1981) Regional perfusion in the treatment of patients with a locally metastasized malignant melanoma of the limbs. Europ J Cancer 17:471–479Google Scholar
  34. 34.
    Nagel K, Junginger T (1987) Extremitätenperfusion beim malignen Melanom. DMW 112:1626–1629Google Scholar
  35. 35.
    Veronesi U, Adamus J, Bandiera DC, Brennhovd O, Caceres E, Cascinelli N, Claudio F, Ikonopisov RL, Javorski VV, Kirov S, Kulakowski A, Lacour J, Lejeune F, Mechl Z, Morabito A, Rodé I, Sergeev S, van Slooten E, Szczygiel K, Trapeznikov NN, Wagner RI (1982) Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 49:2420–2430PubMedGoogle Scholar
  36. 36.
    Manner M, Sinn H, Bubeck H, Kettelhack C, Schlag P (1990) Verbesserte intraoperative Leckkontrolle bei der isolierten Zytostatikaperfusion von Extremitätentumoren. Langenbecks Arch 375:208–213Google Scholar
  37. 37.
    Krauss J, Lange U, Pauer HD, Krauss I (1984) Farbstoffkonzentrationsmessungen zur Abstrombestimmung während und nach der zytostatischen Perfusion zur Behandlung von Extremitätentumoren. Z Exp Chir Transplant Künstl Organe 17:269–274Google Scholar
  38. 38.
    Klaase JM, Kroon BB, van Geel AN, Eggermont AM, Franklin HR, Hart AA (1994) Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 115:39–45PubMedGoogle Scholar
  39. 39.
    Bryant PJ, Balderson GA, Mead P, Egerton WS (1995) Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J Surg 19:363–368PubMedCrossRefGoogle Scholar
  40. 40.
    Clark WH Jr, From L, Bernardino EA, Mihm MC (1969) The histogenesis and biologic behavior of primary malignant melanomas of the skin. Cancer Res 29:705–711PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • Peter Würl
    • 1
  • Uwe Eichfeld
    • 1
  • Hans-Dieter Pauer
    • 1
  • Albrecht Gläser
    • 1
  • Uwe Rose
    • 1
  • Henning Dralle
    • 1
  1. 1.Department of General SurgeryMartin-Luther-University HalleHalleGermany

Personalised recommendations